Sensei Biotherapeutics Inc

NASDAQ:SNSE   3:59:53 PM EDT
7.57
+0.08 (+1.07%)
Products, Other Pre-Announcement

Sensei Biotherapeutics Announces Prioritization Of Next-Generation Multi-Antigenic Immunophage Platform

Published: 06/28/2021 21:00 GMT
Sensei Biotherapeutics Inc (SNSE) - Sensei Biotherapeutics Announces Prioritization of Next-generation Multi-antigenic Immunophage Platform, Monoclonal Antibody and Nanobody Programs.
Sensei Biotherapeutics Inc - Expects Its Cash and Cash Equivalents Will Be Sufficient to Fund Its Operations Into First Half of 2024.
Sensei Biotherapeutics Inc - Company to Focus on Development of Next-generation Phage Product Candidates From Immunophage Platform.
Sensei Biotherapeutics - Look Forward to Initiating Ind-enabling Studies for Sns-vista by End of 2021 and for Sns-401-ng in Second Half of 2022.